Hunan Warrant Pharmaceutical (688799.SH) subsidiary chemical raw material drug Elamomed has been approved for listing.

Hunan Warrant Pharmaceutical (688799.SH) announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Co., Ltd. (referred to as "Chiral Drugs"), has recently received the Approval Notice for the Market Application of Elaromode Active Pharmaceutical Ingredient issued by the National Medical Products Administration (NMPA) (Notice No.: 2026YS00837) and has been publicly disclosed on the "Registration Information Platform for Active Ingredients and Excipients" of the NMPA Center for Drug Evaluation (CDE). Elaromode is the active pharmaceutical ingredient for Elaromode tablets, which are primarily used for the treatment of active rheumatoid arthritis.